Design, synthesis, and structure-activity relationships of novel insulin receptor tyrosine kinase activators

Journal of Medicinal Chemistry

Volumn 51, Issue 19, 2008, Pages 6173-6187

  Lum, Robert T ^a   Cheng, Mingshan ^a   Cristobal, Cristina P ^a   Goldfine, Ira D ^b   Evans, Joseph L ^c   Keck, James G ^a   Macsata, Robert W ^a   Manchem, Vara Prasad ^a   Matsumoto, Yukiharu ^d   Park, Sophia J ^a   Rao, Sandhya S ^a   Robinson, Louise ^a   Shi, Songyuan ^a   Spevak, Wayne R ^a   Schow, Steven R ^a  

^a Telik Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ReceptorBio Inc   (United States)

^d Sanwa Kaguku Kenkyusho Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 [[[7 [[[7 [[(4 CHLORO 3 SULFOPHENYL)AMINO]SULFONYL] 5 HYDROXY (2 NAPHTHYL)]AMINO]CARBONYLAMINO] 4 HYDROXY (2 NAPHTHYL)]SULFONYL]AMINO]BENZENESULFONIC ACID; BENZENESULFONIC ACID DERIVATIVE; ENZYME ACTIVATOR; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME PHOSPHORYLATION; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HYPOINSULINEMIA; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

3T3-L1 CELLS; ADIPOCYTES; ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; BINDING SITES; BLOOD GLUCOSE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; GLUCOSE TOLERANCE TEST; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MOLECULAR STRUCTURE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, INSULIN; STEREOISOMERISM; STREPTOZOCIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; UREA;

EID: 53549121997     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800600v     Document Type: Article

References (45)

1. Zimmet, P.; Alberti, K. G.; Shaw, J. Global and societal implications of the diabetes epidemic. Nature 2001, 414, 782-787.
2. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053.
3. DeFronzo, R. A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997, 5, 177-269.
4. Facchini, F. S.; Hua, N.; Abbasi, F.; Reaven, G. M. Insulin resistance as a predictor of age-related diseases. J. Clin. Endocrinol. Metab. 2001, 86, 3574-3578.
5. Reaven, G. M. Role of insulin resistance in human disease. Diabetes 1988, 37, 1595-1607.
6. Turner, R. C.; Cull, C. A.; Frighi, V.; Holman, R. R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA, J. Am. Med. Assoc. 1999, 281, 2005-2012.
7. Evans, J. L.; Rushakoff, R. J. Oral Pharmacological Agents for Type 2 Diabetes: Sulfonylureas, Meglitinides, Metformin, Thiazolidinediones, α-Glucosidase Inhibitors, and Emerging Approaches. In Endotext.com: Diabetes and Carbohydrate Metabolism, 1st ed.; Degroot, L., Goldfine, I. D., Rushakoff, R. J., Eds.; Medtext, Inc.: Burr Ridge, IL, 2007; http://www.medtext.com.
8. Pfeifer, M.; Halter, J. B.; Beard, J. C.; Porte, D., Jr. Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1981, 53, 1256-1262.
9. Lebovitz, H. E. Insulin Secretagogues: Sulfonylureas and Meglitinides. In Diabetes Mellitus: A Fundamental and Clinical Text, 2nd ed.; LeRoith, D., Taylor, S. I., Olefsky, J. M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000; pp 769-778.
10. Stumvoll, M.; Nurjhan, N.; Perriello, G.; Dailey, G.; Gerich, J. E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995, 333, 550-554.
11. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. F.; Goodyear, L. J.; Moller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108, 1167-1174.
12. Bischoff, H. Pharmacology of alpha-glucosidase inhibition. Eur. J. Clin. Invest. 1994, 24 (Suppl. 3), 3-10.
13. Berger, J.; Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53, 409-435.
14. Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414, 821-827.
15. Sharma, A. M.; Staels, B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 2007, 92, 386-395.
16. Deacon, C. F.; Ahren, B.; Holst, J. J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes. Expert Opin. Invest. Drugs 2004, 13, 1091-1102.
17. Richter, B.; Bandeira-Echtler, E.; Bergerhoff, K.; Clar, C.; Ebrahim, S. H. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2007, CD006063.
18. Devchand, P. R. Glitazones and the cardiovascular system. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15, 188-192.
19. Bolen, S.; Feldman, L.; Vassy, J.; Wilson, L.; Yeh, H. C.; Marinopoulos, S.; Wiley, C.; Selvin, E.; Wilson, R.; Bass, E. B.; Brancati, F. L. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med. 2007, 147, 386-399.
20. Ginsberg, H. N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 2000, 106, 453-458.
21. Kahn, B. B.; Flier, J. S. Obesity and insulin resistance. J. Clin. Invest. 2000, 106, 473-481.
22. Ward, C.; Lawrence, M.; Streltsov, V.; Garrett, T.; McKern, N.; Lou, M. Z.; Lovrecz, G.; Adams, T. Structural insights into ligand-induced activation of the insulin receptor. Acta Physiol. (Oxford) 2008, 192, 3-9.
23. White, M. F. Regulating insulin signaling and beta-cell function through IRS proteins. Can. J. Physiol. Pharmacol. 2006, 84, 725-737.
24. Watson, R. T.; Pessin, J. E. GLUT4 translocation: the last 200 nanometers. Cell. Signalling 2007, 19, 2209-2217.
25. Huang, S.; Czech, M. P. The GLUT4 glucose transporter. Cell Metab. 2007, 5, 237-252.
26. Zhang, B. B.; Salituro, G.; Szalkowski, D.; Li, Z. H.; Zhang, Y.; Royo, I.; Vilella, D.; Diez, M. T.; Pelaez, F.; Ruby, C.; Kendall, R. L.; Mao, X. Z.; Griffin, P.; Calaycay, J.; Zierath, J. R.; Heck, J. V.; Smith, R. G.; Moller, D. E. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284, 974-977.
27. Liu, K.; Xu, L.; Szalkowski, D.; Li, Z.; Ding, V.; Kwei, G.; Huskey, S.; Moller, D. E.; Heck, J. V.; Zhang, B. B.; Jones, A. B. Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor. J. Med. Chem. 2000, 43, 3487-3494.
28. Wood, H. B., Jr.; Black, R.; Salituro, G.; Szalkowski, D.; Li, Z.; Zhang, Y.; Moller, D. E.; Zhang, B. B.; Jones, A. B. The basal SAR of a novel insulin receptor activator. Bioorg. Med. Chem. Lett. 2000, 10, 1189-1192.
29. Qureshi, S. A.; Ding, V.; Li, Z.; Szalkowski, D.; Biazzo-Ashnault, D. E.; Xie, D.; Saperstein, R.; Brady, E.; Huskey, S.; Shen, X.; Liu, K.; Xu, L.; Salituro, G. M.; Heck, J. V.; Moller, D. E.; Jones, A. B.; Zhang, B. B. Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators. J. Biol. Chem. 2000, 275, 36590-36595.
30. Strowski, M. Z.; Li, Z.; Szalkowski, D.; Shen, X.; Guan, X. M.; Juttner, S.; Moller, D. E.; Zhang, B. B. Small-molecule insulin mimetic reduces hyperglycemia and obesity in a nongenetic mouse model of type 2 diabetes. Endocrinology 2004, 145, 5259-5268.
31. Beroza, P.; Damodaran, K.; Lum, R. T. Target-related affinity profiling: Telik's lead discovery technology. Curr. Top. Med. Chem. 2005, 5, 371-381,
32. Manchem, V. P.; Goldfine, I. D.; Kohanski, R. A.; Cristobal, C. P.; Lum, R. T.; Schow, S. R.; Shi, S.; Spevak, W. R.; Laborde, E.; Toavs, D. K.; Villar, H. O.; Wick, M. M.; Kozlowski, M. R. A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes 2001, 50, 824-830.
33. Li, M.; Youngren, J. F.; Manchem, V. P.; Kozlowski, M. R.; Zhang, B. B.; Maddux, B. A.; Goldfine, I. D. Small molecule insulin receptor activators potentiate insulin action in insulin resistant cells. Diabetes 2001, 50, 2323-2328.
34. Koguro, K.; Oga, T.; Mitsui, S.; Orita, R. Novel synthesis of 5-substituted tetrazoles from nitriles. Synthesis 1998, 910-914.
35. Gray, G. W.; Jones, B. The preparation of 4- and 5-n-alkoxy-1- naphthoic and 6- and 7-n-alkoxy-2-naphthoic acids. J. Chem. Soc. 1954, 1954, 678-682.
36. Cheng, M.; Chen, S.; Schow, S. R.; Manchem, V. P.; Spevak, W. R.; Cristobal, C. P.; Shi, S.; Macsata, R. W.; Lum, R. T.; Goldfine, I. D.; Keck, J. G. In vitro and in vivo prevention of HIV protease inhibitor-induced insulin resistance by a novel small molecule insulin receptor activator. J. Cell. Biochem. 2004, 92, 1234-1245.
37. Etter, M. C.; Panunto, T. W. 1,3-Bis(m-nitrophenyl)urea: an exceptionally good complexing agent for proton acceptors. J. Am. Chem. Soc. 1988, 110, 5896-5897.
38. 2O. Cryst. Struct. Commun. 1979, 8, 429-432.
39. Ganis, P.; Avitabile, G.; Benedetti, E.; Pedone, C.; Goodman, M. Crystal and molecular structure of N,N′-diethyl-N,N′- diphenylurea. Proc. Natl. Acad. Sci. U.S.A. 1970, 67, 426-433.
40. Lozanova, C.; Galabov, B.; Ilieva, M.; Vassilev, G. Infrared intensities and conformation of substituted thioureas. J. Mol. Struct. 1984, 115, 427-430.
41. Tanatani, A.; Yamaaguchi, K.; Azumaya, I.; Fukutomi, R.; Shudo, K.; Kagechika, H. N-Methylated diphenylguanidines: conformations, propeller-type molecular chirality, and construction of water-soluble oligomers with multilayered aromatic structures. J. Am. Chem. Soc. 1998, 120, 6433-6422.
42. Carr, A.; Samaras, K.; Chisholm, D. J.; Cooper, D. A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351, 1881-1883.
43. Carr, A.; Samaras, K.; Burton, S.; Law, M.; Freund, J.; Chisholm, D. J.; Cooper, D. A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12, F51-F58.
44. Frost, S. C.; Lane, M. D. Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J. Biol. Chem. 1985, 260, 2646-2652.
45. Clancy, B. M.; Czech, M. P. Hexose transport stimulation and membrane redistribution of glucose transporter isoforms in response to cholera toxin, dibutyryl cyclic AMP, and insulin in 3T3-L1 adipocytes. J. Biol. Chem. 1990, 265, 12434-12443.